Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540595 | 1.00 | AKR1C3 (0.56) | AKR1C3AKR1C1NPC1RAB9APOLB | |
| SCHEMBL20599602 | 0.94 | AKR1C3 (0.50) | AKR1C3AKR1C1NPC1RAB9APOLB | |
| SCHEMBL24434987 | 0.91 | AKR1C3 (0.69) | AKR1C3AKR1C1NPC1RAB9APOLB | |
| SCHEMBL3543298 | 0.91 | AKR1C3 (0.69) | AKR1C3AKR1C1NPC1RAB9APOLB | |
| SCHEMBL28625883 | 0.87 | AKR1C3 (0.78) | AKR1C3AKR1C1NPC1RAB9APOLB | |
| SCHEMBL14113548 | 0.85 | ALDH1A1 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3296229 | 0.85 | ALDH1A1 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3296236 | 0.85 | ALDH1A1 (0.56) | NPC1RAB9AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7986736 | 0.85 | SLC18A3 (0.55) | ALDH1A1SMN1; SMN2HPGDNPSR1KMT2A | |
| SCHEMBL12303028 | 0.84 | ALDH1A1 (0.51) | NPC1RAB9AALDH1A1SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58194841-A | — | — | None | — | — | JP | disclosed |
| JP-58222042-A | — | — | None | — | — | JP | disclosed |
| JP-58180465-A | — | — | None | — | — | JP | disclosed |
| CN-110072860-B | Compounds useful as immunomodulators | 百时美施贵宝公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-3009493-B1 | THERMOCHROMIC COLOR-MEMORIZING COMPOSITION AND THERMOCHROMIC COLOR-MEMORIZING MICROCAPSULE PIGMENT ENCAPSULATING SAME | PILOT INK CO LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| US-8512598-B2 | Liquid crystal compounds and method for preparing the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2013-08-20 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-4452719-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1984-06-05 | — | — | US | disclosed |
| JP-S58222042-A | 4-(TRANS-4-ALKYLCYCLOHEXYL)-1-(4-(TRANS-4- ALKYLOXYMETHYLCYCLOHEXYL)PHENYL)CYCLOHEXENE | CHISSO CORP | 1983-12-23 | — | — | JP | disclosed |
| EP-0094198-A2 | 4-(Trans-4'-alkyloxymethylcyclohexyl) benzoic acid esters | Chisso Corporation (JP) | 1983-11-16 | — | — | EP | disclosed |
| JP-S58194841-A | ESTERS OF 4-(TRANS-4'-ALKYLOXYMETHYLCYCLOHEXYL)BENZOIC ACID | CHISSO CORP | 1983-11-12 | — | — | JP | disclosed |
| JP-S58180465-A | TRANS-4-ALKYLOXYMETHYL-1-(4\"-CYANO-4'-BIPHENYLYL)- CYCLOHEXANE COMPOUND | CHISSO CORP | 1983-10-21 | — | — | JP | disclosed |
| US-4109015-A | PROSTAGLANDINS, LUTEOLYTIC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | AKR1C3 1073/4885AKR1C1 544/4885NPC1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.